Stock Price

As Riot Platforms preps its Q2 earnings call, the real story isn't just Bitcoin. It's a strategic pivot to building the massive infrastructure for our digital future.

A 57% stock plunge and a securities fraud lawsuit against Embecta Corp. reveal the high stakes of corporate guidance and the new era of accountability.

A class-action lawsuit against Futu Holdings exposes the severe risks of China's regulatory crackdown on tech, leaving investors to navigate the fallout.

ADMA Biologics reported 20% growth, but a lawsuit alleges it was a sham built on channel stuffing and hidden deals. Here's what investors need to know.

A health tech innovator can't pay its auditors, triggering a full trading halt. We dissect ARCpoint's crisis and what it means for investors and the market.

Facing delisting pressure, gold miner Blue Gold is deploying a high-stakes playbook. But is its struggle a company-specific issue or a warning for all small-caps?

The specialized REIT surpasses Q2 expectations and raises its 2026 guidance, capitalizing on a surge in defense spending and robust demand for its secure properties.

Geospatial leader ProStar appoints Michael Wolff to transition from founder-led innovation to global market dominance in critical infrastructure mapping.

As PPHC preps for its Q2 results, the strategic communications giant faces a key test. Can its aggressive M&A and strong growth narrative overcome market jitters?

CEO Johan Wattenström paints a picture of unprecedented strength amid a crypto winter, but a closer look reveals a strategy forged in regulatory fire.

The CFO credited with securing $1B for Asante Gold is leaving. His departure puts a spotlight on the miner's ability to fund its ambitious Ghanaian growth plans.

With its $2.2B acquisition of Forte, argenx adds a first-in-class antibody, FB102, expanding its Vision 2030 strategy to redefine autoimmune care.

With its stock down 80% after losing a key contract, Verra Mobility's upcoming Q2 earnings call is a crucial test for its new interim leadership.

As Pacific Financial posts its last independent earnings, the numbers reveal a resilient core overshadowed by merger costs and a shifting economic landscape.

Radiopharm Theranostics secures crucial funding for its promising oncology pipeline, but a sharp stock drop reveals deep investor concerns about dilution.

A new $75 million SPAC has hit the market, but this isn't just another Wall Street vehicle. It's a high-stakes search for the next technology titan.

The e-bike maker reports plunging revenues and a pivot to wholesale, but a history of faked safety certifications and fatal fires haunts its recovery plan.

China SXT Pharma secured $9 million in a direct offering, but a catastrophic stock collapse reveals deep investor distrust in its survival strategy.

The fintech firm is fighting delisting with a reverse split. Stephen Miller analyzes if this cosmetic fix can support its ambitious Bitcoin-centric strategy.

A modest dividend hike from Encompass Health reveals a deeper story of strategic growth, financial discipline, and leadership in a booming rehabilitation market.